TABR Capital Management LLC Invests $3.81 Million in Becton, Dickinson and Company $BDX

TABR Capital Management LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,652 shares of the medical instruments supplier’s stock, valued at approximately $3,814,000.

Several other hedge funds and other institutional investors have also bought and sold shares of BDX. Brighton Jones LLC raised its position in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Oppenheimer Asset Management Inc. grew its position in shares of Becton, Dickinson and Company by 71.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after acquiring an additional 34,437 shares during the period. Transcend Capital Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 88.2% during the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after purchasing an additional 2,715 shares during the last quarter. Belpointe Asset Management LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $650,000. Finally, Assetmark Inc. lifted its stake in Becton, Dickinson and Company by 49.5% in the third quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after purchasing an additional 74,795 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on BDX shares. Bank of America raised their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. Barclays began coverage on Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target for the company. Royal Bank Of Canada set a $175.00 price objective on Becton, Dickinson and Company in a report on Tuesday, April 14th. Citigroup dropped their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Six analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $189.08.

Becton, Dickinson and Company Trading Down 1.1%

NYSE:BDX opened at $156.82 on Wednesday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock’s fifty day moving average price is $164.61 and its two-hundred day moving average price is $183.83. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The company has a market cap of $44.65 billion, a P/E ratio of 25.58, a P/E/G ratio of 11.28 and a beta of 0.29.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, analysts expect that Becton, Dickinson and Company will post 12.55 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were given a dividend of $1.05 per share. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has approved a stock buyback plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity

In other news, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 1,103 shares of company stock valued at $202,870 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.